These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11103927)

  • 1. The social value of health programmes: is age a relevant factor?
    Rodríguez E; Pinto JL
    Health Econ; 2000 Oct; 9(7):611-21. PubMed ID: 11103927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the social importance of concentration or dispersion of individual health benefits.
    Rodríguez-Míguez E; Pinto-Prades JL
    Health Econ; 2002 Jan; 11(1):43-53. PubMed ID: 11788981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
    Rowen D; Brazier J; Mukuria C; Keetharuth A; Risa Hole A; Tsuchiya A; Whyte S; Shackley P
    Med Decis Making; 2016 Feb; 36(2):210-22. PubMed ID: 26670663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating societal concerns for fairness in numerical valuations of health programmes.
    Nord E; Pinto JL; Richardson J; Menzel P; Ubel P
    Health Econ; 1999 Feb; 8(1):25-39. PubMed ID: 10082141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving value measurement in cost-effectiveness analysis.
    Ubel PA; Nord E; Gold M; Menzel P; Prades JL; Richardson J
    Med Care; 2000 Sep; 38(9):892-901. PubMed ID: 10982111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism?
    Birch S; Donaldson C
    Soc Sci Med; 2003 Mar; 56(5):1121-33. PubMed ID: 12593883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a broader view of values in cost-effectiveness analysis of health.
    Menzel P; Gold MR; Nord E; Pinto-Prades JL; Richardson J; Ubel P
    Hastings Cent Rep; 1999; 29(3):7-15. PubMed ID: 10420299
    [No Abstract]   [Full Text] [Related]  

  • 9. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes.
    Donaldson C; Birch S; Gafni A
    Health Econ; 2002 Jan; 11(1):55-70. PubMed ID: 11788982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating quality of life changes into economic evaluations of health care: an overview.
    Blumenschein K; Johannesson M
    Health Policy; 1996 May; 36(2):155-66. PubMed ID: 10158766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
    Richardson JR; Olsen JA
    Health Econ; 2006 Mar; 15(3):311-3; discussion 319-22. PubMed ID: 16389655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inquiry into the relationship between equity weights and the value of the QALY.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2012 Dec; 15(8):1119-26. PubMed ID: 23244815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time preferences for health gains: an empirical investigation.
    Olsen JA
    Health Econ; 1993 Oct; 2(3):257-65. PubMed ID: 8275171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource allocation, social values and the QALY: a review of the debate and empirical evidence.
    Schwappach DL
    Health Expect; 2002 Sep; 5(3):210-22. PubMed ID: 12199660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
    Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
    Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.